SCHEMBL5536032

SCHEMBL5536032

Cc1ccc2c(c1)C(C)(C)CN2C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 13/20 0.43
KDM4E B2RXH2 4/20 0.43
HTT P42858 3/20 0.43
F2 P00734 2/20 0.43
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPT P10636 10/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.38
TSHR P16473 2/20 0.38
POLB P06746 2/20 0.38
ALOX12 P18054 1/20 0.37
PKM P14618 1/20 0.36
CNR1 P21554 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
ALOX15 P16050 1/20 0.35
RARA P10276 1/20 0.33
RARB P10826 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5986105 0.85 ALDH1A1 (0.40) ALDH1A1KDM4EHTTF2GAA
SCHEMBL8293242 0.81 RARA (0.48) ALDH1A1KDM4EHTTF2GAA
SCHEMBL17771804 0.79 SIGMAR1 (0.38) ALDH1A1GAASMN1; SMN2MAPTKMT2A
SCHEMBL19805046 0.79 ALDH1A1 (0.39) ALDH1A1KDM4EHTTF2GAA
SCHEMBL5536025 0.79 NOTUM (0.31) ALDH1A1KDM4EHTTF2GAA
SCHEMBL5468863 0.79 MAPT (0.38) ALDH1A1KDM4EHTTGAASMN1; SMN2
SCHEMBL9917021 0.79 SLC6A2 (0.42) ALDH1A1KDM4E
SCHEMBL17771703 0.79 KDM4E (0.45) ALDH1A1KDM4ESMN1; SMN2MAPTKMT2A
SCHEMBL3308604 0.79 NOTUM (0.43) ALDH1A1KDM4ESMN1; SMN2LMNAPOLB
SCHEMBL17771674 0.78 NPSR1 (0.46) HTTSMN1; SMN2MAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
US-20130087682-A1 PHOTOELECTRIC CONVERSION DEVICE, IMAGING DEVICE, AND METHOD FOR DRIVING PHOTOELECTRIC CONVERSION DEVICE FUJIFILM CORPORATION (JP) 2013-04-11 US disclosed
US-20130087682-A1 PHOTOELECTRIC CONVERSION DEVICE, IMAGING DEVICE, AND METHOD FOR DRIVING PHOTOELECTRIC CONVERSION DEVICE FUJIFILM CORPORATION (JP) 2013-04-11 US disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
US-8378101-B2 Organic semiconductor, photoelectric conversion device, imaging device and novel compounds FUJIFILM CORPORATION (JP) 2013-02-19 US disclosed
US-8378101-B2 Organic semiconductor, photoelectric conversion device, imaging device and novel compounds FUJIFILM CORPORATION (JP) 2013-02-19 US disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-8278650-B2 Organic semiconductor, photoelectric conversion element and image device FUJIFILM CORPORATION (JP) 2012-10-02 US disclosed
US-8278650-B2 Organic semiconductor, photoelectric conversion element and image device FUJIFILM CORPORATION (JP) 2012-10-02 US disclosed
US-20100102303-A1 ORGANIC SEMICONDUCTOR, PHOTOELECTRIC CONVERSION DEVICE, IMAGING DEVICE AND NOVEL COMPOUNDS FUJIFILM CORPORATION (JP) 2010-04-29 US disclosed
US-20100102303-A1 ORGANIC SEMICONDUCTOR, PHOTOELECTRIC CONVERSION DEVICE, IMAGING DEVICE AND NOVEL COMPOUNDS FUJIFILM CORPORATION (JP) 2010-04-29 US disclosed
US-20090283758-A1 ORGANIC SEMICONDUCTOR, PHOTOELECTRIC CONVERSION ELEMENT AND IMAGE DEVICE FUJIFILM CORPORATION (JP) 2009-11-19 US disclosed
US-20090283758-A1 ORGANIC SEMICONDUCTOR, PHOTOELECTRIC CONVERSION ELEMENT AND IMAGE DEVICE FUJIFILM CORPORATION (JP) 2009-11-19 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885KDM4E 4854/4885HTT 4644/4885
US-20100102303-A1 ORGANIC SEMICONDUCTOR, PHOTOELECTRIC CONVERSION DEVICE, IMAGING DEVICE AND NOVEL COMPOUNDS H1-3, H1-4, OR10J3 ALDH1A1 2374/4885KDM4E 3316/4885HTT 2741/4885
US-20090283758-A1 ORGANIC SEMICONDUCTOR, PHOTOELECTRIC CONVERSION ELEMENT AND IMAGE DEVICE H1-0, CCNE1, H1-4 ALDH1A1 1793/4885KDM4E 2903/4885HTT 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.